Hematología y Hemoterapia

Resultados: 387
Tipo Título / Nombre Autor(es) Año
Safety and efficacy of tafasitamab ± lenalidomide added to first-line R?CHOP for DLBCL: Phase 1b First-MIND study Belada D, Kopeckova K, Bergua Burgués JM, Stevens D, André M, Pérez Persona E, et al 2023
Multi-center evaluation of light transmission platelet aggregation reagents: Communication from the ISTH SSC Subcommittee on Platelet Physiology Alessi MC, Coxon C, Ibrahim-Kosta M, Bacci M, Voisin S..., Bermejo N, et al 2023
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry Bernal T, Fernández Moreno A, LaIglesia A de, Benavente C..., Bergua Burgués JM 2023
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E..., Bergua J, et al 2023
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia Simoes C, Villar S, Ariceta B, Garcés JJ, Burgos L..., Bergua JM, et al 2023
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets González Barca E, Tomás-Roca L, Esteve A, Rodríguez M, Gato L..., Bergua Burgués JM, et al 2023
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry Sargas C, Ayala R, Larráyoz MJ, Chillón MC..., Bergua JM 2023
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia Simoes C, Chillon MC, Martínez-Cuadrón D, Calasanz MJ..., Bergua Burgués JM 2023
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C..., Burgues JMB, et al 2023
Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial Richardson PG, Trudel S, Quach H, Popat R..., Casas Avilés I 2022